Literature DB >> 20466523

Blood-brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein.

Louise Karlsson1, Ulrich Schmitt, Martin Josefsson, Björn Carlsson, Johan Ahlner, Finn Bengtsson, Fredrik C Kugelberg, Christoph Hiemke.   

Abstract

According to in vitro studies the enantiomers of venlafaxine display different degrees of serotonin and noradrenaline reuptake inhibition. Therefore, clarification of the enantiomeric drug distribution between serum and brain is highly warranted. To elucidate if P-glycoprotein (P-gp) in a stereoselective manner transports venlafaxine and its metabolites out of the brain we used abcb1ab double-knockout mice that do not express P-gp. A single dose of racemic venlafaxine (10 mg/kg bw) was intraperitoneally injected to knockout (-/-) and wildtype (+/+) mice. Serum and brain samples were collected 1, 3, 6 and 9 h following drug administration for analysis by LC/MS/MS. One to six hours post-dose, the brain concentrations of venlafaxine, O-desmethylvenlafaxine and N-desmethylvenlafaxine were 2-3, 2-6 and 3-12 times higher in abcb1ab (-/-) mice compared to abcb1ab (+/+) mice, respectively. No major differences in the serum and brain disposition of the S- and R-enantiomers of venlafaxine and its metabolites were found between the groups. We conclude that P-gp decreases the penetration of the S- and R-enantiomers of venlafaxine and its major metabolites into the brain. No evidence of a stereoselective P-gp mediated transport of these substances was observed. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20466523     DOI: 10.1016/j.euroneuro.2010.04.004

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  13 in total

Review 1.  PharmGKB summary: venlafaxine pathway.

Authors:  Katrin Sangkuhl; Julia C Stingl; Miia Turpeinen; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-01       Impact factor: 2.089

2.  Development of an enantioselective assay for simultaneous separation of venlafaxine and O-desmethylvenlafaxine by micellar electrokinetic chromatography-tandem mass spectrometry: Application to the analysis of drug-drug interaction.

Authors:  Yijin Liu; Michael Jann; Chad Vandenberg; Chin B Eap; Shahab A Shamsi
Journal:  J Chromatogr A       Date:  2015-10-03       Impact factor: 4.759

3.  Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model.

Authors:  Louise Karlsson; Christoph Hiemke; Björn Carlsson; Martin Josefsson; Johan Ahlner; Finn Bengtsson; Ulrich Schmitt; Fredrik C Kugelberg
Journal:  Psychopharmacology (Berl)       Date:  2010-12-30       Impact factor: 4.530

Review 4.  Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings.

Authors:  Fionn E O'Brien; Timothy G Dinan; Brendan T Griffin; John F Cryan
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

5.  Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir.

Authors:  Michael W Jann; Vicky Spratlin; Kathryn Momary; Hailing Zhang; David Turner; Scott R Penzak; Alan Wright; Chad VanDenBerg
Journal:  Eur J Clin Pharmacol       Date:  2011-12-16       Impact factor: 2.953

6.  The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes.

Authors:  Fen Jiang; Hae-Deun Kim; Han-Sung Na; Seok-Yong Lee; Doo-Won Seo; Jong-Yeol Choi; Ji-Hye Ha; Hee-Jung Shin; Young-Hoon Kim; Myeon-Woo Chung
Journal:  Psychopharmacology (Berl)       Date:  2014-12-17       Impact factor: 4.530

7.  P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents.

Authors:  Fionn E O'Brien; Richard M O'Connor; Gerard Clarke; Timothy G Dinan; Brendan T Griffin; John F Cryan
Journal:  Neuropsychopharmacology       Date:  2013-05-14       Impact factor: 7.853

8.  ABCB1 gene polymorphisms are associated with fatal intoxications involving venlafaxine but not citalopram.

Authors:  L Karlsson; H Green; A L Zackrisson; F Bengtsson; I Jakobsen Falk; B Carlsson; J Ahlner; F C Kugelberg
Journal:  Int J Legal Med       Date:  2013-03-21       Impact factor: 2.686

Review 9.  Pharmacogenetics of chronic pain and its treatment.

Authors:  Svatopluk Světlík; Karolína Hronová; Hana Bakhouche; Olga Matoušková; Ondřej Slanař
Journal:  Mediators Inflamm       Date:  2013-05-20       Impact factor: 4.711

10.  ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression.

Authors:  A B Singh; C A Bousman; C H Ng; K Byron; M Berk
Journal:  Transl Psychiatry       Date:  2012-11-27       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.